Repetitive mild brain trauma accelerates Abeta deposition, lipid peroxidation, and cognitive impairment in a transgenic mouse model of Alzheimer amyloidosis.
Traumatic brain injury (TBI) increases susceptibility to Alzheimer's disease (AD), but it is not known how TBI contributes to the onset or progression of this common late life dementia. To address this question, we studied neuropathological and behavioral consequences of single versus repetitive mild TBI (mTBI) in transgenic (Tg) mice (Tg2576) that express mutant human Abeta precursor protein, and we demonstrate elevated brain Abeta levels and increased Abeta deposition. Nine-month-old Tg2576 and wild-type mice were subjected to single (n = 15) or repetitive (n = 39) mTBI or sham treatment (n = 37). At 2 d and 9 and 16 weeks after treatment, we assessed brain Abeta deposits and levels in addition to brain and urine isoprostanes generated by lipid peroxidation in these mice. A subset of mice also was studied behaviorally at 16 weeks after injury. Repetitive but not single mTBI increased Abeta deposition as well as levels of Abeta and isoprostanes only in Tg mice, and repetitive mTBI alone induced cognitive impairments but no motor deficits in these mice. This is the first experimental evidence linking TBI to mechanisms of AD by showing that repetitive TBI accelerates brain Abeta accumulation and oxidative stress, which we suggest could work synergistically to promote the onset or drive the progression of AD. Additional insights into the role of TBI in mechanisms of AD pathobiology could lead to strategies for reducing the risk of AD associated with previous episodes of brain trauma and for preventing progressive brain amyloidosis in AD patients.
Uryu
Kunihiro
K
Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-4283, USA.
Laurer
Helmut
H
McIntosh
Tracy
T
Praticò
Domenico
D
Martinez
Daniel
D
Leight
Susan
S
Lee
Virginia M-Y
VM
Trojanowski
John Q
JQ
D000544:Alzheimer Disease / Q000150:complications / Q000473:pathology / Q000503:physiopathology*; D016229:Amyloid beta-Peptides / Q000378:metabolism; D016564:Amyloid beta-Protein Precursor / Q000096:biosynthesis / Q000235:genetics; D000686:Amyloidosis / Q000150:complications / Q000473:pathology / Q000503:physiopathology*; D000818:Animals; D001522:Behavior, Animal; D015415:Biomarkers / Q000032:analysis / Q000652:urine; D001921:Brain / Q000473:pathology / Q000503:physiopathology; D001930:Brain Injuries / Q000150:complications / Q000473:pathology / Q000503:physiopathology*; D003072:Cognition Disorders / Q000150:complications / Q000473:pathology / Q000503:physiopathology*; D004195:Disease Models, Animal; D018450:Disease Progression; D004198:Disease Susceptibility / Q000503:physiopathology; D005260:Female; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D016489:Head Injuries, Closed / Q000150:complications / Q000503:physiopathology; D006801:Humans; D028421:Isoprostanes / Q000032:analysis / Q000378:metabolism; D015227:Lipid Peroxidation; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D009043:Motor Activity; D009460:Neurologic Examination; D011930:Reaction Time
D016229:Amyloid beta-Peptides; D016564:Amyloid beta-Protein Precursor; D015415:Biomarkers; D005904:Glial Fibrillary Acidic Protein; D028421:Isoprostanes